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Abstract
Maize MON 87427 9 MON 89034 9 MIR162 9 NK603 (four-event stack maize) was produced by
conventional crossing to combine four single events: MON 87427, MON 89034, MIR162 and NK603. The
GMO Panel previously assessed the four single maize events and four of the subcombinations did not
identify safety concerns. No new data on the single maize events or the four subcombinations that could
lead to modification of the original conclusions on their safety were identified. The molecular
characterisation, comparative analysis (agronomic, phenotypic and compositional characteristics) and the
outcome of the toxicological, allergenicity and nutritional assessment indicate that the combination of the
single maize events and of the newly expressed proteins in the four-event stack maize does not give rise to
food and feed safety and nutritional concerns. The GMO Panel concludes that the four-event stack maize, as
described in this application, is as safe as and nutritionally equivalent to its non-GM comparator and the non-
GM reference varieties tested. In the case of accidental release of viable grains of the four-event stack maize
into the environment, this would not raise environmental safety concerns. The GMO Panel assessed the
likelihood of interactions among the single events in the six maize subcombinations not previously assessed
and concludes that these are expected to be as safe as and nutritionally equivalent to the single events, the
previously assessed subcombinations and the four-event stack maize. The post-market environmental
monitoring plan and reporting intervals are in line with the intended uses of the four-event stack maize.
Post-market monitoring of food/feed is not considered necessary. The GMO Panel concludes that the four-
event stack maize and its subcombinations are as safe as its non-GM comparator and the tested non-GM
reference varieties with respect to potential effects on human and animal health and the environment.
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Summary
Following the submission of application EFSA-GMO-NL-2016-131 under Regulation (EC) No 1829/2003
from Monsanto (hereafter referred to as ‘the applicant’), the Panel on Genetically Modified Organisms of
the European Food Safety Authority (hereafter referred to as the ‘GMO Panel’) was asked to deliver a
scientific opinion on genetically modified (GM) maize MON 87427 9 MON 89034 9 MIR162 9 NK603
(hereafter referred to as ‘four-event stack maize’) and its subcombinations independently of their origin
(referred to hereafter as ‘subcombinations’). The scope of application EFSA-GMO-NL-2016-131 is for the
placing on the market of maize MON 87427 9 MON 89034 9 MIR162 9 NK603 and all its
subcombinations independently of their origin for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to three of the events present in the
four-event stack maize. The safety of subcombinations occurring as segregating progeny in the
harvested grains of maize MON 87427 9 MON 89034 9 MIR162 9 NK603 is assessed in the context
of the assessment of the four-event stack maize. The safety of the subcombinations that either have
been or could be produced by conventional crossing through targeted breeding approaches, and which
can be bred, produced and marketed independently of the four-event stack maize, is assessed
separately in the present scientific opinion.
The four-event stack maize was produced by conventional crossing to combine the four single
events MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein), MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins), MIR162 (expressing the
Vip3Aa20 and the phosphomannose isomerase (PMI) protein) and NK603 (expressing the CP4 EPSPS
protein and its variant CP4 EPSPS L214P) to confer resistance to certain lepidopteran pests and
tolerance to glyphosate-containing herbicides.
The GMO Panel evaluated the four-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring of GM plants. The GMO Panel considered the information submitted in
application EFSA-GMO-NL-2016-131, additional information provided by the applicant during the risk
assessment, the scientific comments submitted by the Member States and the relevant scientific literature.
The previous assessments of the single events MON 87427, MON 89034, MIR162, NK603 and four
of the subcombinations (3 two-event stacks and a three-event stack) provided a basis for the
assessment of the four-event stack maize and the remaining six subcombinations. No safety concerns
were identified by the GMO Panel in the previous assessments. No safety issue concerning the four
single maize events was identified by the updated bioinformatic analyses, nor reported by the
applicant since the publication of the previous GMO Panel scientific opinions. Therefore, the GMO
Panel considers that its previous conclusions on the safety of the single maize events remain valid.
For the four-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analysis of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the post-market
environmental monitoring (PMEM) plan was also undertaken.
The molecular data establish that the events stacked in maize MON 87427 9 MON 89034 9
MIR162 9 NK603 have retained their integrity. Protein expression analyses showed that the levels of the
newly expressed proteins are similar in the four-event stack maize and in the single events, except for the
expected difference for the CP4 EPSPS protein levels resulting from the combination of the MON 87427 and
NK603 single events, both producing CP4 EPSPS protein in the four-event stack. No indications of
interactions that may affect the integrity of the events and the levels of the newly expressed proteins in this
four-event stack maize were identified.
The comparative analysis of forage and grain composition and agronomic/phenotypic characteristics
identified no differences between the four-event stack maize and the non-GM comparator that
required further assessment for food/feed safety or environmental impact.
The molecular characterisation, the comparative analysis and the outcome of the toxicological,
allergenicity and nutritional assessment indicate that the combination of the single maize events and of
the newly expressed proteins in the four-event stack maize does not give rise to food and feed safety
and nutritional concerns. The GMO Panel concludes that the four-event stack maize, as described in
this application, is as safe as and nutritionally equivalent to its non-GM comparator and the non-GM
reference varieties tested.
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Considering the combined events and their potential interactions, the outcome of the comparative
analysis, and the routes and levels of exposure, the GMO Panel concludes that the four-event stack
maize would not raise safety concerns in the case of accidental release of viable GM maize grains into
the environment.
Since no new safety concerns were identified for the four previously assessed subcombinations, and
no new data leading to the modification of the original conclusions on safety were identified, the GMO
Panel considers that its previous conclusions on these maize subcombinations remain valid. For the
remaining six subcombinations included in the scope of application EFSA-GMO-NL-2016-131, no
experimental data were provided. The GMO Panel assessed the possibility of interactions between the
events in the six subcombinations and concludes that these combinations would not raise safety
concerns. These subcombinations are therefore expected to be as safe as and nutritionally equivalent
to the single events, the previously assessed subcombinations and the four-event stack maize.
Based on the relevant publications identified through the literature searches, the GMO Panel does not
identify any safety issue pertaining to the intended uses of maize MON 87427 9 MON 89034
9 MIR162 9 NK603 and its subcombinations. In the context of annual PMEM reports, the applicant should
improve future literature searches according to the GMO Panel recommendations given in this scientific
opinion.
Given the absence of safety concerns for foods and feeds from maize MON 87427 9
MON 89034 9 MIR162 9 NK603 and its subcombinations, the GMO Panel considers that post-market
monitoring of these products is not necessary. The post-market environmental monitoring plan and
reporting intervals are in line with the intended uses of the four-event stack maize and its
subcombinations.
The GMO Panel concludes that maize MON 87427 9 MON 89034 9 MIR162 9 NK603 and its
subcombinations, as described in this application, are as safe as the non-GM comparator and the
tested non-GM reference varieties with respect to potential effects on human and animal health and
the environment.
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1. Introduction
1.1. Background
On 18 February 2016, the European Food Safety Authority (EFSA) received from the Competent
Authority of The Netherlands application EFSA-GMO-NL-2016-131 for authorisation of maize MON 87427 9
MON 89034 9 MIR162 9 NK603 (hereafter referred to as ‘the four-event stack maize’) (Unique Identifier
MON-87427-7 9 MON-89Ø34-3 9 SYN-IR162-4 9 MON-ØØ6Ø3-6), submitted by Monsanto Europe S.A.
(hereafter referred to as ‘the applicant’) according to Regulation (EC) No 1829/2003.1
Following receipt of application EFSA-GMO-NL-2016-131, EFSA informed the EU Member States and
the European Commission and made the summary of the application available to the public on the
EFSA website.2
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and Regulation (EU) No 503/20133 and, when needed, asked the applicant to
supplement the initial application. On 31 May 2016, EFSA declared the application valid and made the
valid application available to EU Member States and the European Commission.
From the validity date, EFSA and its scientific Panel on Genetically Modified Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientific
opinion on application EFSA-GMO-NL-2016-131. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the EU Member States and European Commission (for further details, see the
Section ‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU Member States, including national Competent Authorities within the meaning of Directive
2001/18/EC.4 The EU Member States had three months to make their opinion known on application
EFSA-GMO-NL-2016-131 as of date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientific risk assessment of the four-event stack maize and all its
subcombinations independently of their origin, in the context of their scope as defined in application
EFSA-GMO-NL-2016-131.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation, including the opinions of the nominated
risk assessment bodies of EU Member States.5
In addition to the present scientific opinion on maize MON 87427 9 MON89034 9
MIR162 9 NK603, EFSA and its GMO Panel were also asked to report on the particulars listed under
Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003. The relevant information is made available in
the EFSA Register of Questions,6 including: the information required under Annex II to the Cartagena
Protocol, a labelling proposal and a post-market environmental Monitoring (PMEM) plan as provided by
the applicant; the method(s), validated by the Community reference laboratory, for detection, including
sampling and identification of the transformation event in the food-feed and/or foods-feeds produced
from it; and the appropriate reference materials.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online at the EFSA Register of Questions (http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocume
ntsLoader?question=EFSA-Q-2016-00148).
3 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L 157, 8.6.2013, p. 1–48.
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
5 Opinions of the nominated risk assessment bodies of EU Member States can be found at the EFSA Register of Questions
(http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2016-00148).
6 http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2016-00148
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2. Data and methodologies
2.1. Data
The GMO Panel based its scientific assessment of the four-event stack maize and subcombinations
on application EFSA-GMO-NL-2016-131, additional information provided by the applicant during the risk
assessment, scientific comments submitted by Member States and relevant peer-reviewed scientific
publications. As part of this comprehensive information package, the GMO Panel received additional
unpublished studies submitted by the applicant in order to comply with the specific provisions of
Regulation (EU) No 503/2013. A list of these additional unpublished studies is provided in Appendix B.
2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU) No
503/2013, its applicable guidelines (EFSA GMO Panel, 2010a, 2011a,b, 2015a) and explanatory notes
(EFSA, 2017a,b) for the risk assessment of GM plants. During its risk assessment, the GMO
Panel considered all additional unpublished studies as listed in Appendix B for potential effects on
human and animal health and the environment.
For the assessment of 90-day animal feeding studies, the GMO Panel took into account the criteria
included in the EFSA guidance (EFSA Scientific Committee, 2011) and the explanatory statement for its
applicability (EFSA, 2014).
The GMO Panel also assessed the applicant’s literature searches, which include a scoping review, in
accordance with the recommendations on literature searching outlined in EFSA (2010, 2017a).
In the frame of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2016-131 covers the four-event stack maize MON 87427 9 MON 89034 9
MIR162 9 NK603 and all its 10 subcombinations independently of their origin (Table 1). The scope of this
application is for food and feed uses, import and processing, and excludes cultivation within the European
Union (EU).
The term ‘subcombination’ refers to any combination of up to three of the maize events MON
87427, MON 89034, MIR162 or NK603.
The safety of subcombinations occurring as segregating progeny in harvested grains of the four-
event stack maize is evaluated in the context of the assessment of the four-event stack maize in
Section 3.4 of the present scientific opinion.
‘Subcombination’ also covers combinations that have either been or could be produced by
conventional crossing through targeted breeding approaches (EFSA GMO Panel, 2011a). These are
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-NL-2016-131
Degree of Stacking Events
Four-event stack maize MON 87427 9 MON 89034 9 MIR162 9 NK603
Three-event stack maize MON 87427 9 MON 89034 9 MIR162
MON 87427 9 MON 89034 9 NK603
MON 87427 9 MIR162 9 NK603
MON 89034 9 MIR162 9 NK603
Two-event stack maize MON 87427 9 MON 89034
MON 87427 9 NK603
MON 87427 9 MIR162
MON 89034 9 NK603
MON 89034 9 MIR162
MIR162 9 NK603
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maize stacks that can be bred, produced and marketed independently of the four-event stack maize.
These subcombinations are assessed in Section 3.5 of this scientific opinion.
The four-event stack maize was produced by conventional crossing to combine four single maize
events: MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein);
MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins); MIR162 (expressing the Vip3Aa20 and
phosphomannose isomerase (PMI) proteins); and NK603 (expressing the CP4 EPSPS protein and the
variant CP4 EPSPS L214P) to confer resistance to certain lepidopteran pests and tolerance to glyphosate-
containing herbicides. It should be noted that the assessment of herbicide residues in maize herbicide-
tolerant crops relevant for this application has been investigated by the EFSA Pesticides Unit (EFSA, 2018).
All four single maize events, the two-event stacks MON 89034 9 NK603, MON 87427 9 NK603 and
MON 87427 9 MON 89034 and the three-event stack MON 87427 9 MON 89034 9 NK603 have been
previously assessed by the GMO Panel (see Table 2), and no safety concerns were identified.
3.2. Updated information on the single events7
Since the publication of the scientific opinions on the single maize events (see Table 2), no safety
issue concerning the four single events has been reported by the applicant.
Updated bioinformatic analyses for maize events MON 87427, MON 89034, MIR162 and NK603
confirmed that no known endogenous genes were disrupted by any of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed CP4 EPSPS,
Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins confirm previous results indicating no significant
similarities to toxins or allergens7. Updated bioinformatics analyses of the newly created open reading
frames (ORFs) within the inserts or spanning the junctions between the insert and the flanking regions for
maize events MON 87427, MON 89034, MIR162 and NK603 confirmed previous analyses (Table 2). These
analyses indicate that the expression of an ORF showing significant similarities to toxins or allergens for
any of the events in maize MON 87427 9 MON 89034 9 MIR162 9 NK603 is highly unlikely (Table 2).
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis to microbial DNA for maize events MON
87427, MON 89034, MIR162 and NK603. The likelihood and potential consequences of plant-to-
bacteria gene transfer are described in Section 3.4.4.2.
Based on the above information, the EFSA GMO Panel considers that its previous conclusions on
the safety of the single maize events remain valid.
3.3. Systematic literature review8
The GMO Panel assessed the applicant’s literature searches on maize MON 87427 9 MON 89034 9
MIR162 9 NK603, which include a scoping review, according to the guidelines given in EFSA (2010).
A systematic review as referred to in Regulation (EU) No 503/2013 has not been provided in
support to the risk assessment of the application EFSA-GMO-NL-2016-131. Based on the outcome of
Table 2: Single maize events and subcombinations of maize MON 87427 9 MON 89034 9
MIR162 9 NK603 previously assessed by the GMO Panel
Event Application or mandate EFSA Scientific Opinion
MON 87427 EFSA-GMO-BE-2012-110 EFSA GMO Panel (2015b)
MON 89034 EFSA-GMO-NL-2007-37 EFSA (2008)
MIR162 EFSA-GMO-DE-2010-82 EFSA GMO Panel (2012)
NK603 CE/ES/00/01
EFSA-GMO-NL-2005-22
EFSA-GMO-RX-NK603
EFSA (2004, 2007)
EFSA (2009)
EFSA (2009)
MON 89034 9 NK603 EFSA-GMO-NL-2007-38 EFSA GMO Panel (2009)
MON 87427 9 MON 89034 EFSA-GMO-BE-2013-117 EFSA GMO Panel (2017a)
MON 87427 9 NK603 EFSA-GMO-BE-2013-117 EFSA GMO Panel (2017a)
MON 87427 9 MON 89034 9 NK603 EFSA-GMO-BE-2013-117 EFSA GMO Panel (2017a)
7 Dossier: Part II – Sections 1.2.2.2 and 1.2.2.5; additional information: 11/7/2017, 23/11/2018 and 22/3/2019.
8 Dossier: Part II – Section 7; additional information: 18/7/2017, 14/9/2017, 25/9/2017, 20/12/2017, 30/11/2018 and 25/3/2019.
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the scoping review, the GMO Panel agrees that there is limited value of undertaking a systematic
review for maize MON 87427 9 MON 89034 9 MIR162 9 NK603 at present.
Although the overall quality of the performed literature searches is acceptable, the GMO
Panel considers that future searches on maize MON 87427 9 MON 89034 9 MIR162 9 NK603 should
be improved. The GMO Panel therefore recommends the applicant to:
• ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientific terminology, common typos, translation issues);
• use truncation consistently.
None of the relevant publications identified through the literature searches reported information
pointing to safety issues associated with the intended uses of maize MON 87427 9 MON 89034 9
MIR162 9 NK603.
3.4. Risk assessment of the four-event stack maize MON 87427 3
MON 89034 3 MIR162 3 NK603
3.4.1. Molecular characterisation9
In line with the requirements laid down by Regulation (EU) No 503/2013, the possible impact of
the combination of the events on their integrity, the expression levels of the newly expressed proteins
or the biological functions conferred by the individual inserts are considered below.
3.4.1.1. Genetic elements and their biological function
Maize events MON 87427, MON 89034, MIR162 and NK603 were combined by conventional
crossing to produce maize MON 87427 9 MON 89034 9 MIR162 9 NK603. The structure of the
inserts introduced into the four-event stack maize is described in detail in the respective EFSA scientific
opinions (Table 2) and no new genetic modifications were involved. Genetic elements in the expression
cassettes of the single events are summarised in Table 3.
Intended effects of the inserts in maize MON 87427 9 MON 89034 9 MIR162 9 NK603 are
summarised in Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Cry1A.105, Cry2Ab2 and Vip3Aa20
proteins in susceptible insects.
Table 3: Genetic elements in the expression cassettes of events stacked in maize MON
87427 9 MON 89034 9 MIR162 9 NK603
Event Promoter 5’ UTR Transit peptide Coding region Terminator
MON 87427 35S
(CaMV)
– CTP2 (Arabidopsis
thaliana)
CP4 epsps*
(Agrobacterium sp.)
nos
(Agrobacterium
tumefaciens)
MON 89034 35S
(CaMV)
cab
(Triticum sp.)
– cry1A.105
(Bacillus thuringiensis)
hsp17
(Triticum sp.)
35S
(FMV)
– CTP
(Zea mays)
cry2Ab2
(B. thuringiensis)
nos
(A. tumefaciens)
MIR162 ZmUbiInt
(Z. mays)
– – vip3Aa20
(B. thuringiensis)
35S
(CaMV)
ZmUbiInt
(Z. mays)
– – pmi
(Escherichia coli)
nos
(A. tumefaciens)
NK603 ract1
(Oryza sativa)
ract1
(O. sativa)
CTP2
(A. thaliana)
CP4 epsps*
(Agrobacterium sp.)
nos
(A. tumefaciens)
35S
(CaMV)
I-Hsp70
(Z. mays)
CTP2
(A. thaliana)
CP4 epsps L214P
(Agrobacterium sp.)
nos
(A. tumefaciens)
CaMV: cauliflower mosaic virus; FMV: Figwort Mosaic Virus; CTP: chloroplast transit peptide; UTR: untranslated region.
–: When no element was specifically introduced to optimise expression.
*: Codon-optimised for expression in plants.
9 Dossier: Part II – Section 1.2.2; additional information: 6/7/2016 and 10/1/2017.
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Table 4: Characteristics and intended effects of the events stacked in maize MON 87427 9 MON
89034 9 MIR162 9 NK603
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MON
87427
CP4 EPSPS Based on a gene from Agrobacterium strain
CP4 (Barry et al., 2001). 5-enolpyruvyl-
shikimate-3-phosphate synthase (EPSPS) is
an enzyme involved in the shikimic acid
pathway for aromatic amino acid
biosynthesis in plants and microorganisms
(Herrmann, 1995)
Event MON 87427 expresses the bacterial CP4
EPSPS protein which confers tolerance to
glyphosate-containing herbicides as it has
lower affinity towards glyphosate than the
plant endogenous enzyme
MON
89034
Cry1A.105
Cry2Ab2
Based on genes from Bacillus thuringiensis
subsp. kurstaki and subsp. aizawai.
B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Schnepf et al., 1998; Ellis et al., 2002)
Based on a gene from Bacillus thuringiensis
subsp. kurstaki. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event MON 89034 expresses a modified
version of the Cry1A-type protein. Cry1A.105
is a protein toxic to certain lepidopteran
larvae feeding on maize
Event MON 89034 expresses the Cry2Ab2, a
protein toxic to certain lepidopteran larvae
feeding on maize
MIR162 Vip3Aa20
PMI
Based on a gene from Bacillus thuringiensis
strain AB88 (Estruch et al., 1996). In
addition to Cry proteins, B. thuringiensis
also produces insecticidal proteins during its
vegetative growth stage. These are referred
to as vegetative insecticidal proteins (Vip)
(Fang et al., 2007)
Based on a gene from E. coli. The
phosphomannose isomerase (PMI) enzyme
catalyzes the isomerisation of mannose-6-
phosphate to fructose-6-phosphate and
plays a role in the metabolism of mannose
(Markovitz et al., 1967)
Event MIR162 expresses a modified version of
the B. thuringiensis vip3Aa1 gene, and
encodes Vip3Aa20, a protein toxic to certain
lepidopteran larvae feeding on maize
Event MIR162 expresses PMI, which is used
as selectable marker. Mannose normally
inhibits root growth, respiration and
germination. Transformed cells expressing
PMI are able to utilise mannose as a carbon
source (Negrotto et al., 2000)
NK603 CP4 EPSPS
CP4 EPSPS
L214P
Based on a gene from Agrobacterium strain
CP4 (Barry et al., 2001). 5-
enolpyruvylshikimate-3-phosphate synthase
(EPSPS) is an enzyme involved in the
shikimic acid pathway for aromatic amino
acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Based on a gene from Agrobacterium strain
CP4 (Barry et al., 2001). 5-
enolpyruvylshikimate-3-phosphate synthase
(EPSPS) is an enzyme involved in the
shikimic acid pathway for aromatic amino
acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event NK603 expresses the bacterial CP4
EPSPS protein which confers tolerance to
glyphosate-containing herbicides as it has
lower affinity towards glyphosate than the
plant endogenous enzyme
Event NK603 expresses a modified version of
the bacterial CP4 EPSPS protein which confers
tolerance to glyphosate-containing herbicides
as it has lower affinity towards glyphosate
than the plant endogenous enzyme
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3.4.1.2. Integrity of the events in the four-event stack maize
The genetic stability of the inserted DNA over multiple generations in the single maize events MON
87427, MON 89034, MIR162 and NK603 was previously demonstrated (see Table 2). Integrity of these
genetically independent events in maize MON 87427 9 MON 89034 9 MIR162 9 NK603 was
demonstrated by polymerase chain reaction (PCR) and sequence analysis, which show that the
sequences of the events (inserts and their flanking regions) in the four-event stack maize are identical
to the sequences originally reported for the four single events.
3.4.1.3. Information on the expression of the inserts
CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI protein levels were analysed by enzyme-linked
immunosorbent assay (ELISA) in material harvested from a field trial at five locations in the USA in
2013. Samples analysed included leaf (V2–V4), whole plant (V10–V11), root (V2–V4 and R5), forage
(R5), pollen (R1) and grain (R6) both those treated and not treated with glyphosate.
In order to assess the changes in protein expression levels which may result from potential
interactions between the events, protein levels were determined for the four-event stack and the
corresponding single events in different parts of the plant.
The levels of all the newly expressed proteins in the four-event stack maize were comparable to
those of the single events, except for the expected differences in the CP4 EPSPS protein levels
resulting from the combination of single events MON 87427 and NK603 both producing CP4 EPSPS
protein in the four-event stack maize (Appendix A). Therefore, there is no indication of interactions
that may affect the levels of the newly expressed proteins in this stack.
3.4.1.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in maize MON 87427 9 MON
89034 9 MIR162 9 NK603 have retained their integrity. Protein expression analyses showed that the
levels of the newly expressed proteins are comparable in the four-event stack and in the single events
except for CP4 EPSPS, which showed in general the expected higher levels in the stack resulting from
the combination of the single events MON 87427 and NK603. Therefore, there is no indication of
interaction that may affect the integrity of the events or the levels of the newly expressed proteins in
this stack.
Based on the known biological function of the newly expressed proteins, the only foreseen
interactions at the biological level are between the Cry and Vip3Aa20 proteins in susceptible insects,
which will be dealt with in Section 3.4.4.
3.4.2. Comparative analysis10
3.4.2.1. Overview of studies conducted for the comparative analysis
Application EFSA-GMO-NL-2016-131 presents data on agronomic and phenotypic characteristics, as
well as on forage and grain composition of the four-event stack maize (Table 5).
Table 5: Overview of the comparative analysis studies to characterise the four-event stack maize
provided in application EFSA-GMO-NL-2016-131
Study focus Study details Comparator
Non-GM reference
varieties
Agronomic and phenotypic analysis Field study, USA, 2013, eight sites(a) MPA640B 17 (b)
Compositional analysis
(a): The field trials were located in Jefferson, IA; Stark, IL; Shelby IL; Clinton IN; Polk, NE; York, NE; Lehigh, PA and Walworth,
WI.
(b): Non-GM maize hybrids used in the 2013 field trials (for both the agronomic/phenotypic and the compositional analysis):
Burrus 645, Dekalb DKC59-34, Dekalb DKC63-43, Gateway 4148, Gateway 6158, H-9180, Legacy L7671, Lewis 6442, Lewis
7007, LG2597, Midland Phillips 7B15P, Mycogen 2M746, NC + 5220, Phillips 717, Stewart S588, Stewart S602 and Stine 9724.
10 Dossier: Part II – Section 1.3; additional information: 29/9/2016 and 21/4/2017.
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3.4.2.2. Experimental field trial design and statistical analysis
At each site, the following materials were grown: the four-event stack maize, the comparator maize
MPA640B and four commercial non-GM maize reference varieties (henceforth, non-GM reference
varieties). All materials were treated with conventional herbicides management regimes; in addition,
the field trials included the four-event stack maize exposed to the intended glyphosate-containing
herbicide on top of the conventional herbicides.
The agronomic, phenotypic and compositional data were analysed as specified by EFSA GMO
Panel (EFSA GMO Panel, 2010b, 2011a). This includes, for each of the two treatments of the four-
event stack maize, the application of a difference test (between the GM stack maize and its non-GM
comparator) and an equivalence test (between the GM stack maize and the set of non-GM reference
varieties).11 The results of the equivalence test are categorised into four possible outcomes (I–IV,
ranging from equivalence to non-equivalence).12
3.4.2.3. Suitability of selected test materials
Selection of the GM maize line and comparator
To produce the four-event stack maize, the single events MON 87427, MON 89034, MIR162 and
NK603 were transferred in the genetic background of two different non-GM maize inbred lines, LH244
and LH287.
In subsequent subsections, maize MON 87427 9 MON 89034 9 MIR162 9 NK603 refers to the
hybrid (F1) obtained crossing the GM inbred line LH244 (carrying MIR162) with the GM inbred line
LH287 (carrying MON 87427 9 MON 89034 9 NK603).
The comparator selected in the field trials is the hybrid maize MPA640B that was obtained by
crossing the non-GM inbred lines LH244 and LH287. As documented by the pedigree and by the
requested additional information, the EFSA GMO Panel considers the selected comparator acceptable
for the comparative analysis.
The four-event stack maize and the non-GM comparator, both with a comparative relative maturity
(CRM) of 110, are appropriate for growing in a range of environments across North America.
Selection of non-GM reference varieties
The 17 non-GM reference varieties (see Table 5) with a CRM ranging from 109 to 115 were
selected by the applicant and at each field trial site four of them were tested. On the basis of the
information provided on the CRM, the GMO Panel considers the selected non-GM reference varieties
appropriate for the comparative assessment.
Seed production and quality
The seeds of the four-event stack maize and the comparator used in the 2013 field trials (see
Table 5) were produced, harvested and stored under similar conditions. The seed lots were verified for
their identity via event specific PCR analysis. No indications of possible differences in germination
capacity (early stand count) were identified under open field conditions (see Section 3.4.2.5). The
GMO Panel considers that the starting seed used as test material in the agronomic, phenotypic and
compositional studies were of acceptable quality.
Conclusion on suitability
The GMO Panel is of the opinion that the four-event stack maize, the non-GM comparator and the
non-GM maize reference varieties were properly selected and are of adequate quality. Therefore, the
test materials are considered suitable for the comparative analysis.
11 The purpose of the test of equivalence is to evaluate the estimated mean values for maize MON 87427 9 MON 89034 9
MIR162 9 NK603 taking into account natural variability as defined by a set of commercial non-GM maize reference varieties with
a history of safe use for consumption as food or feed.
12 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
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3.4.2.4. Representativeness of the receiving environments
Selection of field trial sites
The selected field trial sites were located in commercial maize-growing regions of North America.
The soil characteristics of the selected fields were diverse,13 corresponding to optimal and near-optimal
conditions for maize cultivation (Sys et al., 1993). The GMO Panel considers that the selected sites
reflect commercial maize-growing regions in which the test materials are likely to be grown.
Meteorological conditions
Maximum and minimum mean temperatures and sum of precipitations were provided on a monthly
basis. An exceptional weather condition was reported at one of the selected site.14 However, due to
the lack of major impacts on plant growth at this site, the GMO Panel considers that the exceptional
weather conditions did not invalidate the selection of the field trial sites for the comparative analyses.
Management practices
The field trials included plots containing four-event stack maize, plots with the comparator and
plots with non-GM reference varieties, all managed according to local agricultural practices. In
addition, the field trials included plots containing the four-event stack maize managed following the
same agricultural practices, plus exposed to the intended glyphosate-containing herbicide. Glyphosate
was applied at the V2–V4 growth stage. The GMO Panel considers that the management practices,
including sowing, harvesting and application of plant protection products, were appropriate.
Conclusion on representativeness
The GMO Panel concludes that the geographical locations, soil characteristics, meteorological
conditions and management practices of the field trials are typical for the receiving environments
where the test materials could be grown.
3.4.2.5. Agronomic and phenotypic characteristics
Thirteen agronomic and phenotypic endpoints,15 plus information on abiotic stressors, disease
incidence and arthropod damage, were collected from eight different sites (Table 5).
The results of the statistical analysis (Section 3.4.2.2) were the following:
• For maize MON 87427 9 MON 89034 9 MIR162 9 NK603 (treated with conventional
herbicides), the test of difference identified statistically significant differences with the non-GM
comparator for days to 50% pollen shed, ear height, test weight and yield. All the four
endpoints fell under equivalence category I.
• For maize MON 87427 9 MON 89034 9 MIR162 9 NK603 (treated with the intended
herbicide), a statistically significant difference with the non-GM comparator was identified for
test weight, which fell under equivalence category I.
3.4.2.6. Compositional analysis
Maize forage and grains harvested from the field trials in the USA in 2013 were analysed for
78 different constituents (9 in forage and 69 in grains), including the key constituents recommended
by the OECD (2002). Fifteen grain constituents with more than 50% of the observations below the
limit of quantification were excluded from the statistical analysis.16
13 Soil types of the field trials were silty clay loam, silt loam and loam. Soil organic matter ranged from 2.0% to 3.4%.
14 Frost event occurred prior to harvest at Walworth County, Wisconsin.
15 Early stand count, days to 50% pollen shed, days to 50% silking, stay green rating, ear height, plant height, dropped ears,
stalk lodged plants, root lodged plants, final stand count, grain moisture, test weight and yield.
16 These were: sodium, furfural, caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), myristic acid (C14:0), myristoleic
acid (C14:1), pentadecanoic acid (C15:0), pentadecenoic acid (C15:1),), heptadecenoic acid (C17:1), heptadecadienoic acid
(C17:2), c-linolenic acid (C18:3), eicosadienoic acid (C20:2), eicosatrienoic acid (C20:3) and arachidonic acid (C20:4).
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The statistical analysis (Section 3.4.2.2) was applied to the remaining 63 constituents (9 in forage17
and 54 in grains18). A summary of the outcome of the test of difference and the test of equivalence is
presented in Table 6:
• For maize MON 87427 9 MON 89034 9 MIR162 9 NK603 (untreated), the test of difference
identified statistically significant differences from the non-GM comparator for 30 constituents (3
in forage and 27 in grains). The level of all 30 constituents fell under equivalence category I or II.
• For maize MON 87427 9 MON 89034 9 MIR162 9 NK603 (treated), statistically significant
differences between the stacked maize event and the non-GM comparator were identified for
28 constituents (2 in forage and 26 in grains). The level of all 28 constituents fell under
equivalence category I or II.
The GMO Panel assessed all significant differences between the four-event stack maize and the
non-GM comparator, taking into account the potential impact on plant metabolism and the natural
variability observed for the set of non-GM reference varieties. No endpoints showing significant
differences between the four-event stack maize and the non-GM comparator and falling under
category III/IV were identified.
Table 6: Outcome of the comparative compositional analysis in grains and forage of maize MON
87427 9 MON 89034 9 MIR162 9 NK603. The table shows the number of endpoints in
each category
Test of difference(a)
Not Treated(c) Treated(c)
Not
different
Significantly
different
Not
different
Significantly
different
Test of
equivalence(b)
Category I/II 31 30(d) 33 28(d)
Category III/IV 1(e) –(f) 1(e) –(f)
Not categorised 1(g) –(h) 1(g) –(h)
Total endpoints 63 63
(a): Comparison between the four-event stack maize and the non-GM comparator.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not treated with the intended herbicide glyphosate (see Section 3.4.2.4).
(d): Endpoints with significant differences between the four-event stack maize and its non-GM comparator and falling in
equivalence category I-II. For grain, both treated and not treated: alanine, phytic acid, raffinose, arachidic acid (C20:0),
eicosenoic acid (C20:1), behenic acid (C22:0), TDF, iron, manganese, phosphorus, potassium, zinc, ash, carbohydrates,
protein, total fat, ferulic acid, ß-carotene, pyridoxine and a-tocopherol. For not treated only: threonine, palmitic acid
(C16:0), calcium, copper, magnesium, folic acid and riboflavin. For treated only: isoleucine, methionine, stearic acid (C18:0),
linolenic acid (C18:3), ADF and thiamine. For forage, both treated and not treated: calcium and moisture. For not treated
only: phosphorus.
(e): Endpoints with no significant differences between the four-event stack maize and its non-GM comparator and falling in
equivalence category III/IV: palmitoleic acid (C16:1) in grain.
(f): Endpoints with significant differences between the four-event stack maize and its non-GM comparator and falling in
equivalence category III/IV: none.
(g): Endpoints not categorised for equivalence and without significant differences between the four-event stack maize and its
non-GM comparator: serine in grain.
(h): Endpoints not categorised for equivalence and with significant differences between the four-event stack maize and its
non-GM comparator: none.
17 Crude protein, crude fat, crude fibre, acid detergent fibre (ADF), neutral detergent fibre (NDF), ash, carbohydrates, calcium
and phosphorus.
18 Proximates and fibre fractions (moisture, ash, protein, total fat, carbohydrates, acid detergent fibre (ADF), neutral detergent
fibre (NDF) and total dietary fibre (TDF)), amino acids (alanine, arginine, aspartic acid, cystine, glutamic acid, glycine,
histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine),
fatty acids (palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2),
linolenic acid (C18:3), arachidic acid (C20:0), behenic acid (C22:0) and eicosenoic acid (C21:0)), minerals (calcium, copper,
iron, magnesium, manganese, phosphorus, potassium and zinc), vitamins (folic acid, niacin, pyridoxine, riboflavin, thiamine,b-
carotene and a-tocopherol) and other compounds (ferulic acid, p-coumaric acid, phytic acid and raffinose).
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3.4.2.7. Conclusion on the comparative analysis
Taking into account the natural variability observed for the set of non-GM reference varieties, the
GMO Panel concludes that:
• None of the differences identified in the agronomic and phenotypic characteristics tested
between the four-event stack maize and the non-GM comparator needs further assessment for
environmental safety.
• None of the differences identified in forage and grain composition between the four-event
stack maize and the non-GM comparator needs further assessment for food/feed safety.
3.4.3. Food and feed safety assessment19
3.4.3.1. Effects of processing
Maize MON 87427 9 MON 89034 9 MIR162 9 NK603 will undergo existing production processes
used for conventional maize. No novel production process is envisaged. Based on the outcome of the
comparative assessment, processing of the four-event stack maize into food and feed products is not
expected to result in products being different from those of conventional non-GM maize varieties.
3.4.3.2. Influence of temperature and pH on newly expressed proteins
The effects of temperature and pH on the newly expressed proteins in this four-event stack maize
have been previously evaluated by the GMO Panel (Table 2).
3.4.3.3. Toxicology
Testing newly expressed proteins
Five proteins (Cry1A.105, Cry2Ab, PMI, Vip3Aa20, CP4 EPSPS and its variant CP4 EPSPS L214P) are
newly expressed in the four-event stack maize (Section 3.4.1). The GMO Panel has previously assessed
these proteins in the context of the single events (Table 2), and no safety concerns were identified for
humans and animals. The GMO Panel is not aware of any new information that would change this
conclusion.
The potential for a functional interaction between the proteins newly expressed in maize
MON 87427 9 MON 89034 9 MIR162 9 NK603 has been assessed with regard to human and animal
health. The insecticidal proteins Cry1A.105 and Cry2Ab2 are delta-endotoxins acting through cellular
receptors found in target insect species. It is reported that the gastrointestinal tract of mammals,
including humans, lacks receptors with high specific affinity to Cry proteins (Hammond et al., 2013;
Koch et al., 2015). The Vip3Aa20 protein is a protein secreted by Bacillus thuringiensis during its
vegetative phase acting in target insects via a mechanism similar to that of Cry proteins (Chakroun
et al., 2016; Bel et al., 2017). The CP4 EPSPS and PMI proteins are enzymes that catalyse distinct
biochemical reactions and act on unrelated substrates in the plant with high substrate specificity.
On the basis of the known biological function of the individual newly expressed proteins (Table 4),
there is currently no expectation for possible interactions relevant to the food and feed safety of the
four-event stack maize.
In vitro protein degradation studies on Cry1A.105, Cry2Ab, PMI, Vip3Aa20, CP4 EPSPS and its
variant CP4 EPSPS L214P proteins have been previously evaluated by the GMO Panel (Table 2).
The GMO Panel concludes that there are no safety concerns to human and animal health related to
the newly expressed proteins Cry1A.105, Cry2Ab, PMI, Vip3Aa20, CP4 EPSPS and its variant CP4
EPSPS L214P in the four-event stack maize.
Testing of new constituents other than newly expressed proteins
No new constituents other than newly expressed proteins have been identified in the four-event
stack maize. Therefore, no further food and feed safety assessment of components other than the
newly expressed proteins is required.
19 Dossier: Part II – Sections 1.4, 1.5, 1.6 and Section 2; additional information: 16/10/2018, 8/11/2018, 22/3/2019 and 26/3/
2019.
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Information on altered levels of food and feed constituents
The four-event stack maize did not show any compositional differences to the non-GM comparator
that would require further assessment (Section 3.4.2.6).
Testing of the whole genetically modified food and feed
Based on the outcome of the molecular characterisation assessment, comparative analysis and
toxicological assessment, no indication of findings relevant to food/feed safety related to the stability
and expression of the inserts or to interaction between the transformation events, and no
modifications of toxicological concern in the composition of the four-event stack maize have been
identified (see above and Sections 3.4.1 and 3.4.2). Therefore, animal studies on food/feed derived
from the four-event stack maize are not necessary (EFSA GMO Panel, 2011a).
In accordance to Regulation (EU) No 503/2013, the applicant provided a 90-day oral repeated-dose
toxicity study in rats on whole food and feed from each of the maize single-event MON 87427, MON
89034, MIR162 and NK603. The four studies had already been provided in the context of the single-
event applications and assessed by the GMO Panel; no adverse effects related to the administration of
the respective GM diets had been identified (Table 2). In the context of the assessment of this four-
event stack maize and in order to fulfil the requirements of Regulation (EU) No 503/2013 for 90-day
studies, the applicant provided additional information upon EFSA’s request: missing information on test
material and diets for all the studies; evaluation of the cage effect in the study on MIR162; additional
histopathological analysis for the studies on MON 87427 and MON 89034.
These studies are adapted from OECD TG 408 (OECD, 1998) and comply with the principles of
Good Laboratory Practice (GLP), except for the lack of analytical determination of concentration,
homogeneity and stability of the test item in the formulated diets. It is recognised that it may not
always be technically possible to generate information on homogeneity and concentration for a test
item administrated or formulated, and the lack of such data and its impact on the validity of a study
should be justified (OECD, 2018). The GMO Panel acknowledges that there are no practical methods
available to analytically determine these for complex test items such as maize in formulated diets and
considers adequate the application of proper diet preparation procedures and regular evaluations of
the mixing methods. Based on the additional information received from the applicant the GMO
Panel considers that the diet preparation procedures in place in the facilities where the diets for the
90-day studies on MON 87427, MON 89034, MIR162 and NK603 were prepared guaranteed their
homogeneity and the proper concentration of the respective test or control items. As regards the
stability of the test item (maize grains) in the diets, the applicant considers that in accordance to
product expiration standards declared by the diet manufacturer the constituents of the diets used in
these studies are stable for the duration of the treatment. The GMO Panel considers this justification
acceptable. In addition, the GMO Panel notes that even though the diets were prepared and analysed
in non-GLP facilities, standardised procedures and quality measures were followed. Therefore, the
GMO Panel considers that this is not a major deviation impacting these studies.
Regarding the 90-day feeding study in rats on MIR162, the applicant also confirmed the identity of
the test material and diets and provided grain compositional analysis. The GMO Panel notes that the
applicant detected and measured the levels of the newly expressed proteins in maize MIR162 in
the test diets after the completion of the 90-day study; the GMO Panel considers that this supports the
confirmation of the identity and the stability of the test item and diets. The original statistical analysis
(based on individual animals) was complemented by an analysis based on cage mean values for
endpoints showing a statistically significant cage effect (between-cage variation larger than within-cage
variation).20 In this additional analysis, no statistically significant differences were identified between
rats given the test diets and controls.
Regarding the 90-day studies in rats on MON 89034 and on MON 87427, in the tissues and organs
newly examined21 sporadic histopathological findings were observed and are considered compatible
with the spontaneous background pathology of rats of this strain and age.
20 Body weight (day 7, week 3,7,8,10 and 11); basophil count, eosinophil count, other cells, reticulocytes, landing foot splay,
adrenal gland absolute and relative weight, spleen absolute weight.
21 Aorta, bone (sternum) with bone marrow, cecum, cervix (females only), eyes with optic nerves, lung (including bronchi),
mandibular lymph node, Peyer’s Patches, skin with mammary gland (females only), skin from males (similar area), oesophagus,
pituitary, prostate (males only), mandibular salivary gland, seminal vesicles (males only), skeletal muscle, trachea, urinary
bladder, uterus (females only), and vagina (females only) from all animals given the control and 33% test diet.
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The GMO Panel noted that the incorporation rate of maize selected in these studies is up to 41.5%,
in line with commercially available rodent diets. It has been recently reported that a diet incorporating
50% maize may be tolerated without inducing nutritional imbalances in rats after 90-day
administration (Steinberg et al., 2019) but the GMO Panel considers that further scientific confirmation
is needed before this 50% maize incorporation rate is generally applicable.
On the basis of the additional information received, the GMO Panel concludes that these studies are
in line with the requirements of Regulation (EU) 503/2013 and confirms its previous conclusions, i.e.
that there are no indications of adverse effects related to the 90-day administration to rats of diets
including grains from maize MON 87427 (33%), MON 89034 (up to 33%) MIR162 (up to 41%) and
NK603 (up to 33%).
3.4.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufficient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a; Regulation (EU) No 503/2013). In addition, when known functional aspects of the
newly expressed protein or structural similarity to known adjuvants may indicate an adjuvant activity,
the possible role of these proteins as adjuvants is considered. When newly expressed proteins with a
potential adjuvant activity are expressed together, possible interactions increasing adjuvanticity and
impacting the allergenicity of the GM crop are assessed.
Assessment of allergenicity of the newly expressed proteins
For allergenicity, the GMO Panel has previously evaluated the safety of the Cry1A.105, Cry2Ab2,
PMI, Vip3Aa20 and CP4 EPSPS (including its variant CP4 EPSPS L214P) proteins individually, and no
concerns on allergenicity were identified in the context of the applications assessed (Table 2). No
new information on allergenicity of these proteins that might change the previous conclusions of the
GMO Panel has become available. Based on the current knowledge, and as none of the newly
expressed proteins showed allergenicity, no reasons for concerns regarding the simultaneous
presence of these newly expressed proteins in this four-event stack maize affecting their allergenicity
are expected.
For adjuvanticity, the Bt protein Cry1Ac have been suggested to possess adjuvant activity based on
animal studies on Cry1Ac when applied at relatively high doses (e.g. Vazquez et al., 1999). The GMO
Panel has previously evaluated the safety of the Cry1A.105, Cry2Ab and Vip3Aa20 proteins and no
concerns on adjuvanticity were identified in the context of the applications assessed (Table 2). The
levels of individual Bt proteins in this four-event stack maize are comparable to those in the respective
single maize events (see Section 3.4.1.3). From the limited experimental evidence available, the GMO
Panel did not find indications that the presence of the Bt proteins at the levels expressed in this four-
event stack maize might act as adjuvants with the potential to enhance a specific immunoglobulin E
(IgE) response and to favour the development of an allergic reaction.
Assessment of allergenicity of GM plant products
The EFSA GMO Panel regularly reviews the available publications on food allergy to maize.
However, maize is not considered a common allergenic food (OECD, 2002).22 Therefore, the EFSA
GMO Panel does not request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see above and
Sections 3.4.1 and 3.4.2), the GMO Panel identified no indications of a potentially increased
allergenicity of food and feed derived from the four-event stack maize with respect to that derived
from the non-GM comparator.
22 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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3.4.3.5. Dietary exposure assessment of new constituents
In line with Regulation (EU) No 503/2013, the applicant provided dietary exposure estimates to CP4
EPSPS (CP4 EPSPS and CP4 EPSPS L214P), Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI proteins newly
expressed in MON 87427 9 MON 89034 9 MIR162 9 NK603 maize. Dietary exposure was estimated
based on protein expression levels reported in this application for the four-event stack maize treated
with the intended herbicide, the current available consumption data and feed practices, the foods and
feeds currently available on the market and the described processing conditions.
Table 7 describes the protein expression levels used to estimate both human and animal dietary
exposure.
Human dietary exposure
Dietary exposure was estimated across different European countries on different population groups:
young population (infants, toddlers, ‘other children’), adult population (adolescents, adults, elderly and
very elderly) and special populations (pregnant and lactating women).
For the purpose of estimating dietary exposure, the levels of newly expressed proteins in MON
87427 9 MON 89034 9 MIR162 9 NK603 maize grains were derived from replicated field trials (four
replicates from five locations) in the 2013 US growing season. Mean values (fresh weight) are
considered as the most adequate to estimate dietary exposure (see Table 7). Since no specific
consumption data were available on commodities containing, consisting of or obtained from MON
87427 9 MON 89034 9 MIR162 9 NK603 maize grains, a conservative scenario with 100%
replacement of conventional maize by the GM maize was considered. Consumption figures for all
relevant commodities (e.g. corn flakes, sweet corn, popcorn, etc.) were retrieved from the EFSA
Comprehensive European Food Consumption Database (EFSA consumption database).23 Maize oil was
excluded from the assessment since no proteins are expected to be present in the oil.
For the acute dietary exposure estimations, the applicant assigned to the processed commodities
the mean value reported for the newly expressed proteins in maize grains. This is a conservative
approach as neither recipes nor the effect of processing is considered on the final concentration of
newly expressed proteins. Summary statistics from the EFSA consumption database were used.24
Acute dietary exposure was estimated using for each population group the food commodity with the
highest acute consumption among consumers only (95th or 97.5th percentile depending on the
number of consumers), and multiplying this value by the mean values of CP4 EPSPS, Cry1A.105,
Cry2Ab2, Vip3Aa20, and PMI proteins (EFSA, 2011). Table 8 shows the highest acute dietary exposure
for the different newly expressed proteins; dietary exposure estimates ranged between 2.2 lg/kg body
weight (bw) per day for Cry2Ab2 in adults (18–65 years) and 466.7 lg/kg bw per day for Vip3Aa20 in
toddlers (1–3 years). The most relevant food commodities in terms of contribution to the exposure
were sweet corn (toddlers) and popcorn (adults).
Table 7: Mean values (n = 20, lg/g dry weight and lg/g fresh weight) for newly expressed
proteins in grains and forage from MON 87427 9 MON 89034 9 MIR162 9 NK603 maize
treated with the intended herbicide(a)
Protein
Tissue/developmental stage
Grains/R6
(lg/g dry weight and lg/g fresh weight)
Forage/R5
(lg/g dry weight)
CP4 EPSPS(b) 13.0/12.0 300.0
Cry1A.105 2.4/2.1 32.0
Cry2Ab2 0.69/0.6 29.0
Vip3Aa20 59.0/51.9(c) 100.0
PMI 1.4/1.2(c) 4.4
(a): Intended herbicide: glyphosate.
(b): CP4 EPSPS levels in MON 87427 9 MON 89034 9 MIR162 9 NK603 maize are the sum of two protein variants, CP4 EPSPS
(expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
(c): Fresh weight values for Vip3Aa20 and PMI proteins used to estimate human dietary exposure were calculated by multiplying the
dry weight values by a dry weight correction factor of 0.88 to account for approximately 12%moisture content in the grains.
23 http://www.efsa.europa.eu/en/data/food-consumption-data
24 Summary statistics from the EFSA Comprehensive European Food Consumption Database accessed in September 2015.
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The GMO Panel estimated chronic dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20,
and PMI proteins. Individual consumption data of the relevant food commodities were retrieved from
the EFSA Consumption Database, using dietary surveys with at least two days consumption and
covering a total of 22 European countries.25 Different recipes and factors were considered to estimate
the amount of maize in the consumed commodities before assigning CP4 EPSPS, Cry1A.105, Cry2Ab2,
Vip3Aa20, and PMI proteins levels to the relevant commodities.26 No losses in the newly expressed
proteins (NEPs) during processing were considered, except for certain commodities excluded from the
exposure estimations (maize oil, corn starch, corn syrup). The 95th percentile chronic exposure (highly
exposed population) was derived from the distribution of the individual dietary exposure estimates
within each dietary survey and age class. Table 9 shows the chronic dietary exposure to each of the
newly expressed proteins across European dietary surveys; dietary exposure ranged between
0.005 lg/kg bw per day for Cry2Ab2 protein in elderly and very elderly population (> 65 years) and
233.3 lg/kg bw per day for Vip3Aa20 protein in infants (< 1 year). Main average contributors to the
exposure in the dietary surveys with the highest estimates were sweet corn in infants, and cornflakes
in toddlers and ‘Other children’.
Animal dietary exposure
Animal dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI proteins was
estimated following the consumption of maize grain, gluten feed, gluten meal and maize forage/silage
since these are the maize products entering the feed chain. A conservative scenario with 100%
replacement of conventional maize products by the GM products was considered.
Table 8: Highest acute dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI
proteins (lg/kg bw per day) estimated across European dietary surveys and different age
classes
Acute dietary exposure (lg/kg bw per day)
CP4 EPSPS(a) Cry1A.105 Cry2Ab2 Vip3Aa20 PMI
Toddlers 107.9 18.9 5.6 466.7 11.7
Adults 42.1 7.4 2.2 182.2 4.3
bw: body weight; EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase.
(a): CP4 EPSPS levels in MON 87427 9 MON 89034 9 MIR162 9 NK603 maize are the sum of two protein variants, CP4 EPSPS
(expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
Table 9: Range of chronic dietary exposure estimates (95th percentiles, highly exposed population)
to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI proteins (lg/kg bw per day)
across European dietary surveys and different age classes
N
Chronic dietary exposure (lg/kg bw per day)
CP4 EPSPS(a) Cry1A.105 Cry2Ab2 Vip3Aa20 PMI
Infants 11 0–53.9 0.0–9.3 0.0–2.8 0.0–233.3 0.0–5.4
Toddlers 14 2.9–50.2 0.5–8.6 0.2–2.6 12.7–217.0 0.3–5.0
Other children 19 8.0–44.0 1.4–7.6 0.4–2.3 34.4–190.2 0.8–4.4
Adolescents 18 1.7–32.9 0.3–5.7 0.1–1.7 7.3–142.4 0.2–3.3
Adults 19 0.8–16.6 0.1–2.9 0.04–0.9 3.4–71.6 0.1–1.7
Elderly and very elderly 18 0.1–10.2 0.02–1.8 0.005–0.5 0.4–44.1 0.01–1.0
Special population(b) 4 4.9–24.0 0.9–4.1 0.3–1.2 21.1–103.8 0.5–2.4
bw: body weight; n: number of dietary surveys; EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase.
(a): CP4 EPSPS levels in MON 87427 9 MON 89034 9 MIR162 9 NK603 maize are the sum of two protein variants, CP4 EPSPS
(expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
(b): Pregnant women and lactating women
25 Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Germany, Denmark, Estonia, Finland, France, the United Kingdom,
Greece, Croatia, Hungary, Ireland, Italy, Latvia, the Netherlands, Portugal, Spain, Romania, and Sweden.
26 Example: 100 g of maize bread are made with approximately 74 g of maize flour, and a reverse yield factor of 1.22 from the
conversion of maize grains into flour is used. This results in 47.2 µg of Vip3Aa20 per gram of maize bread as compared to
51.9 µg/g in the maize grains.
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Mean levels of CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI proteins in maize grains and
forage/silage were derived from field trials conduct in the 2013 US growing season (see Table 7). To
estimate the mean NEP levels in maize gluten feed and gluten meal, a factor of 2.6 and 7.1 folds
respectively was applied, based on the protein content of gluten feed and gluten meal relative to
maize grain (OECD, 2002), assuming that no losses of NEP occur during processing.
Dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI proteins in maize MON
87427 9 MON 89034 9 MIR162 9 NK603 following the consumption of maize grain, gluten feed and
gluten meal was provided by the applicant across different animal species (i.e. broiler, finishing pig and
lactating dairy cattle), based on estimates for animal body weight, daily feed intake and inclusion rates
(percentage) of maize grain, gluten feed and gluten meal in animal diets (OECD, 2009). Estimated
dietary exposure was as follows:
• to CP4 EPSPS protein, 1,532 lg/kg bw per day in broiler chickens, 1,250 lg/kg bw per day in
dairy cattle and 753 lg/kg bw per day in finishing pig.
• to Cry1A.105 protein, 283 lg/kg bw per day in broiler chickens, 231 lg/kg bw per day in dairy
cattle and 139 lg/kg bw per day in finishing pig.
• to Cry2Ab2 protein, 81 lg/kg bw per day in broiler chickens, 66 lg/kg bw per day in dairy
cattle and 40 lg/kg bw per day in finishing pig.
• to Vip3Aa20 protein, 6,955 lg/kg bw per day in broiler chickens, 5,673 lg/kg bw per day in
dairy cattle and 3,416 lg/kg bw per day in finishing pig.
• to PMI protein, 165 lg/kg bw per day in broiler chickens, 135 lg/kg bw per day in dairy cattle
and 81 lg/kg bw per day in finishing pig.
The GMO Panel estimated dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI
proteins in maize MON 87427 9 MON 89034 9 MIR162 9 NK603 across different livestock animal
species (beef and dairy cow, lamb, breeding swine and layer) following the consumption of maize
forage/silage, based on estimates for animal body weight, daily feed intake and inclusion rates of
maize forage/silage in animal diets (OECD, 2009).
Estimated dietary exposure was as follows:
• to CP4 EPSPS protein, 5,760 lg/kg bw per day in beef, 6,923 lg/kg bw per day in dairy cow,
3,825 lg/kg bw per day in lamb, 1,385 lg/kg bw per day in breeding swine and 2,052 lg/kg
bw per day in layer.
• to Cry1A.105 protein, 614 lg/kg bw per day in beef, 738 lg/kg bw per day in dairy cow,
408 lg/kg bw per day in lamb, 147 lg/kg bw per day in breeding swine and 219 lg/kg bw
per day in layer.
• to Cry2Ab2 protein, 557 lg/kg bw per day in beef, 670 lg/kg bw per day in dairy cow,
370 lg/kg bw per day in lamb, 134 lg/kg bw per day in breeding swine and 198 lg/kg bw
per day in layer.
• to Vip3Aa20 protein, 1,920 lg/kg bw per day in beef, 2,307 lg/kg bw per day in dairy cow,
1,257 lg/kg bw per day in lamb, 461 lg/kg bw per day in breeding swine and 684 lg/kg bw
per day in layer.
• to PMI protein, 84 lg/kg bw per day in beef, 101 lg/kg bw per day in dairy cow, 56 lg/kg bw
per day in lamb, 20 lg/kg bw per day in breeding swine and 30 lg/kg bw per day in layer.
3.4.3.6. Nutritional assessment of endogenous constituents
The intended traits of the four-event stack maize are herbicide tolerance and insect resistance, with
no intention to alter nutritional parameters. Comparison of the composition of maize MON 87427 9
MON 89034 9 MIR162 9 NK603 with the non-GM comparator and non-GM reference varieties did not
identify differences that would require further safety assessment. From these data, the GMO
Panel concludes that the nutritional impact of maize MON 87427 9 MON 89034 9 MIR162 9 NK603-
derived food and feed is the same as that expected from the non-GM comparator and non-GM
reference varieties.
3.4.3.7. Conclusion of the food and feed safety assessment
The newly expressed proteins Cry1A.105, Cry2Ab, PMI, Vip3Aa20, CP4 EPSPS and its variant CP4
EPSPS L214P in maize MON 87427 9 MON 89034 9 MIR162 9 NK603 do not raise safety concerns
for human and animal health. Interactions between these newly expressed proteins raising food and
feed safety concerns (toxicological, allergenicity and adjuvanticity) are not expected. The nutritional
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impact of the four-event stack maize foods and feeds is expected to be the same as those from the
non-GM comparator and non-GM reference varieties. The GMO Panel concludes that the four-event
stack maize, as described in this application, is as safe as and nutritionally equivalent to the non-GM
comparator and the non-GM reference varieties tested.
3.4.4. Environmental risk assessment27
Considering the scope of application EFSA-GMO-NL-2016-131, which excludes cultivation, the
environmental risk assessment (ERA) of the four event stack maize mainly takes into account: (1) the
exposure of microorganisms to recombinant DNA in the gastrointestinal tract of animals fed GM
material and of microorganisms present in environments exposed to faecal material of these animals
(manure and faeces); and (2) the accidental release into the environment of viable four event stack
maize grains during transportation and/or processing (EFSA GMO Panel, 2010a).
3.4.4.1. Persistence and invasiveness of the GM plant
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2003). Field observations indicate that
maize grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent
crops (e.g. Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers
have been shown to grow weakly and flower asynchronously with the maize crop (Palaudelmas et al.,
2009). Thus, the establishment and survival of feral and volunteer maize in the EU is currently limited
and transient.
It is unlikely that the intended traits of event the four-event stack maize will provide a selective
advantage to maize plants, except when they are exposed to glyphosate-containing herbicides or
infested by insect pests that are susceptible to the Cry1A.105, Cry2Ab2 and/or Vip3Aa20 proteins.
However, this fitness advantage will not allow the GM plant to overcome other biological and abiotic
factors (described above) limiting plant’s persistence and invasiveness. Therefore, the presence of the
intended traits will not affect the persistence and invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that the four-event stack maize will differ
from conventional maize hybrid varieties in its ability to survive until subsequent seasons, or to
establish occasional feral plants under European environmental conditions in case of accidental release
into the environment of viable grains of the four-event stack maize.
3.4.4.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene flow via cross-pollination from feral
plants originating from spilled grains.
Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel Scientific Opinions (see Table 2). This assessment included consideration of
homology-based recombination processes, as well as non-homologous end joining and microhomology-
mediated end joining. Possible fitness advantages that the bacteria in the receiving environments
would gain from acquiring recombinant DNA were considered. No concern as a result of an unlikely,
but theoretically possible, HGT of the recombinant genes to bacteria in the gut of domesticated
animals and humans fed GM material or other receiving environments was identified. The applicant
submitted an updated bioinformatic analysis for each of the single events to assess the possibility for
HGT by homologous recombination.
The updated bioinformatics analyses of events MON 87427, MON 89034, MIR162 and NK603 do
not reveal any new DNA sequence that could provide sufficient length and identity which could
facilitate HGT by double homologous recombination, confirming the conclusions of previous Scientific
Opinions (EFSA GMO Panel, 2017a,b, 2019a,b,c).
27 Dossier: Part II – Section 5.
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Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage were not
identified.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this four-event stack maize to bacteria does not raise any environmental
safety concern.
Plant-to-plant gene transfer
The potential for occasional feral GM maize MON 87427 9 MON 89034 9 MIR162 9 NK603 plants
originating from grain import spills to transfer recombinant DNA to sexually compatible plants and the
environmental consequences of this transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
flowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA,
2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes, and/or maize-teosinte hybrids, occurring in cultivated areas
(EFSA, 2016, Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.4.4.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is
considered extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the
opinion that environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe will not differ from that of conventional maize varieties.
3.4.4.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-NL-2016-131 (no cultivation), potential interactions of
occasional feral four-event stack maize plants arising from grain import spills with the target organisms
are not considered a relevant issue.
3.4.4.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled four-event stack maize grains is limited, and because ingested
proteins are degraded before entering the environment through faecal material of animals fed GM
maize, potential interactions of the four-event stack maize with non-target organisms are not
considered by the GMO Panel to raise any environmental safety concern. Interactions that may occur
between the Cry or Vip proteins (as mentioned in Section 3.4.1.4) will not alter this conclusion.
3.4.4.5. Interactions with abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled grains or occasional feral four-event stack maize
plants arising from grain import spills is limited, and because ingested proteins are degraded before
entering the environment through faecal material of animals fed GM maize, potential interactions with
the abiotic environment and biogeochemical cycles are not considered by the GMO Panel to raise any
environmental safety concern.
3.4.4.6. Conclusion of the environmental risk assessment
The GMO Panel concludes that it is unlikely that the four-event stack maize would differ from
conventional maize varieties in its ability to persist under European environmental conditions.
Considering the scope of the application EFSA-GMO-NL-2016-131, interactions of occasional feral four-
event stack maize plants with the biotic and abiotic environment are not considered to be relevant
issues. The analysis of HGT from the four-event stack maize to bacteria does not indicate a safety
concern. Therefore, considering the combined traits and their interactions, the outcome of the
comparative analysis, and the routes and levels of exposure, the GMO Panel concludes that the four-
event stack maize would not raise safety concerns in the event of accidental release of viable GM
maize grains into the environment.
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3.4.5. Conclusion on the four-event stack maize MON 87427 3
MON 89034 3 MIR162 3 NK603
No new data on the four single maize events MON 87427, MON 89034, MIR162 and NK603 that
would lead to a modification of the original conclusions on their safety were identified.
The combination of maize events MON 87427, MON 89034, MIR162 and NK603 in the four-event
stack maize did not give rise to issues pertaining to the molecular, agronomic/phenotypic or
compositional characteristics of the four-event stack maize that would be of concern for food and feed
safety and nutrition.
The newly expressed proteins in the four-event stack maize do not raise safety concerns for human
and animal health and the environment in light of the scope of this application.
No indications of interactions between the events based on the biological functions of the newly
expressed proteins that would raise a safety issue were identified in maize MON 87427 9 MON 89034 9
MIR162 9 NK603. Comparison of the levels of the newly expressed proteins between the four-event
stack maize and those of the single maize events did not reveal an interaction at protein expression level.
Considering the combined traits and their interactions, the outcome of the comparative analysis,
and the routes and levels of exposure, the GMO Panel concludes that maize
MON 87427 9 MON 89034 9 MIR162 9 NK603 would not raise safety concerns in the event of
accidental release of viable GM maize grains into the environment.
No scientific information that could change the conclusions on this four-event stack maize was
retrieved through systematic literature searches covering the 10 years before submission of the
application and the period since the time of validity of the application. The GMO Panel concludes that
maize MON 87427 9 MON 89034 9 MIR162 9 NK603, as described in this application, is nutritionally
equivalent to and as safe as the comparator and the non-GM reference varieties tested.
3.5. Risk assessment of the subcombinations28
Subcombinations previously assessed in the frame of other applications are discussed in
Section 3.5.1. The strategy followed for the subcombinations that have not been previously assessed
(Section 3.5.2) has been described by the GMO Panel.29 In this case, the risk assessment takes as its
starting point the assessment of the single maize events, and uses the data generated for the four-
event stack as well as all the additional data available on subcombinations previously assessed by the
GMO Panel (Table 2).
3.5.1. Subcombinations previously assessed
The GMO Panel has previously assessed four subcombinations (3 two-events stacks and a three-
event stack; see Table 2) and did not identify any safety concern. Literature searches covering the
10 years before submission of application EFSA-GMO-NL-2016-131 (February 2006-February 2016) and
the period since the time of validity of the application revealed no new scientific information relevant
to the risk assessment of these maize stacks. Consequently, the GMO Panel considers that its previous
conclusions on these subcombinations remain valid.
3.5.2. Subcombinations not previously assessed
Of the 10 subcombinations included in the scope of application EFSA-GMO-NL-2016-131, six have
not been assessed by the GMO Panel (see Table 10). No experimental data were provided for these
maize stacks.
28 Dossier: Part II – Section 7; additional information: 24/5/2018 and 23/3/2019.
29 115th GMO Panel meeting (Annex 1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
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3.5.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the single maize events has
been previously demonstrated (see Table 2). Integrity of the events was demonstrated in maize
MON 87427 9 MON 89034 9 MIR162 9 NK603 (Section 3.4.1.2) and the previously assessed maize
subcombinations (EFSA GMO Panel, 2009, EFSA GMO Panel, 2017a). The GMO Panel finds no reasons
to expect the loss of integrity of the events in the maize subcombinations not previously assessed (see
Table 10).
3.5.2.2. Expression of the events
The GMO Panel assessed whether the combination of any of the four events by conventional
crossing could result in significant changes in expression levels of the newly expressed proteins, as this
could indicate an interaction between the events. Based on current knowledge of the molecular
elements introduced, there is no reason to expect interactions that would affect the levels of the newly
expressed proteins in the subcombinations compared with those in the single maize events. This
assumption was confirmed by comparing the levels of the newly expressed proteins of each single
maize event with those of the four-event stack maize. The levels were similar in the four-event stack
maize and in the single events except for CP4 EPSPS, which showed, in general, the expected higher
level in the stack resulting from the combination of the single events MON 87427 and NK603
(Section 3.4.1.3 and Appendix A). Therefore, there was no indication of an interaction at protein
expression level. In addition, expression data from the two-event stack maize MON 89034 9 NK603
(EFSA GMO Panel, 2009) and the three-event stack maize MON 87427 9 MON 89034 9 NK603 (EFSA
GMO Panel, 2017a) were similar to those observed in each of the single maize events or showed in
general the expected higher levels for CP4 EPSPS resulting from the combination of the single events
MON 87427 and NK603 both producing CP4 EPSPS protein in the three-event stack. This supports the
conclusion that interactions affecting expression levels of the newly expressed proteins are not
expected in the maize subcombinations not previously assessed and included in the scope of
application EFSA-GMO-NL-2016-131.
3.5.2.3. Potential interactions between the events
The GMO Panel assessed the potential for interactions between maize events in the six
subcombinations not previously assessed (Table 10), taking into consideration the intended traits and
unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there
is currently no expectation for possible interactions relevant for the food/feed or environmental safety
between these proteins in those subcombinations. The GMO Panel also took into account all the
intended and potential unintended effects considered in the assessment of the four single events, the
previously assessed subcombinations (Table 2) and the four-event stack maize. It is concluded that
none of these events would raise safety concerns when combined in any of these maize
subcombinations. The GMO Panel considers that no further data are needed to complete the
assessment of subcombinations from the four-event stack maize.
3.5.3. Conclusion
Since no new safety concerns were identified for the previously assessed subcombinations, the
GMO Panel considers that its previous conclusions on these maize subcombinations remain valid. For
the remaining six subcombinations included in the scope of application EFSA-GMO-NL-2016-131, no
Table 10: Subcombinations not previously assessed and covered by the scope of application EFSA-
GMO-NL-2016-131
Degree of stacking Events
Three-event stack maize MON 87427 9 MON 89034 9 MIR162
MON 87427 9 MIR162 9 NK603
MON 89034 9 MIR162 9 NK603
Two-event stack maize MON 87427 9 MIR162
MON 89034 9 MIR162
MIR162 9 NK603
Assessment of maize MON 87427 3 MON 89034 3 MIR162 3 NK603 and subcombinations
www.efsa.europa.eu/efsajournal 25 EFSA Journal 2019;17(7):5734
experimental data have been provided. For these subcombinations, the GMO Panel assessed the
possibility of interactions between the events and concluded that these combinations would not raise
safety concerns. These subcombinations are therefore expected to be as safe as and nutritionally
equivalent to the single maize events, the previously assessed subcombinations and the four-event
stack maize.
3.6. Post-market monitoring30
3.6.1. Post-market monitoring of GM food/feed
The GMO Panel concluded that the four-event stack maize, as described in this application, is
nutritionally equivalent to and as safe as the non-GM comparator and the non-GM reference varieties
tested (Section 3.4.3.7). Four of the subcombinations have been previously assessed and no safety
concerns were identified. The six subcombinations not previously assessed and included in the scope
of application EFSA-GMO-NL-2016-131 are expected to be as safe as and nutritionally equivalent to the
single maize events, the previously assessed maize subcombinations and the four-event stack maize
(Section 3.5.3). Therefore, the GMO Panel considers that post-market monitoring of food and feed
from the four-event stack maize and its subcombinations, as described in this application, is not
necessary.
3.6.2. Post-market environmental monitoring
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC, are: (1) to confirm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the ERA are correct; and (2) identify the occurrence
of adverse effects of the GMO, or its use, on human health or the environment that were not
anticipated in the ERA.
Monitoring is related to risk management, and thus a final adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientific rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from the four-event stack
maize, no case-specific monitoring is required.
The PMEM plan proposed by the applicant for the four-event stack maize includes: (1) the
description of a monitoring approach involving operators (federations involved in import and
processing), reporting to the applicant, via a centralised system, any observed adverse effect(s) of
GMOs on human health and the environment; (2) a coordinating system established by EuropaBio for
the collection of information recorded by the various operators; and (3) the review of relevant
scientific publications retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The
applicant proposes to submit a PMEM report on an annual basis and a final report at the end of the
authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of the four-event stack maize. The GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plan. The PMEM plan and reporting intervals are in line
with the intended uses of the four-event stack maize and its subcombinations.
In the context of annual PMEM reports, the applicant should improve future literature searches
according to the GMO Panel recommendations given in Section 3.3.
3.6.3. Conclusion on post-market monitoring
No post market monitoring of food and feed is necessary. The scope of the PMEM plan provided by
the applicant and the reporting intervals are in line with the intended uses of maize
MON 87427 9 MON 89034 9 MIR162 9 NK603.
4. Overall conclusions
The GMO Panel was asked to carry out a scientific assessment of maize MON 87427 9 MON
89034 9 MIR162 9 NK603 and subcombinations for import, processing and food and feed uses in
accordance with Regulation (EC) No 1829/2003.
30 Dossier: Part II – Sections 4 and 6; additional information: 29/9/2016 and 13/12/2016.
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No new information on the four single maize events MON 87427, MON 89034, MIR162 and NK603
that would lead to a modification of the original conclusions on their safety were identified.
The molecular characterisation, the comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins in the four-event
stack maize does not give rise to food/feed safety and nutritional concerns. The GMO Panel concludes
that the four-event stack maize, as described in this application, is as safe as and nutritionally
equivalent to its non-GM comparator and the non-GM reference varieties tested.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from the four-event stack maize into the environment.
Since no new data on the four subcombinations previously assessed (3 two-event stacks and a
three-event stack) that would lead to a modification of the original conclusions on their safety were
identified, the GMO Panel considers that its previous conclusions on these maize stacks remain valid.
For the remaining six subcombinations included in the scope of application EFSA-GMO-NL-2016-131, no
information has been provided. The GMO Panel assessed possible interactions between the events in
the six subcombinations, and concludes that these combinations of events MON 87427, MON 89034,
MIR162 and NK603 would not raise safety concerns. These subcombinations are therefore expected to
be as safe as and nutritionally equivalent to the maize single events, the previously assessed
subcombinations and the four-event stack maize.
Based on the relevant publications identified through the literature searches, the GMO Panel did not
identify any safety issues pertaining to the intended uses of maize MON 87427 9 MON
89034 9 MIR162 9 NK603 and its subcombinations. In the context of annual PMEM reports, the
applicant should improve future literature searches according to the GMO Panel recommendations.
In addition, the GMO Panel considered the additional unpublished studies listed in Appendix B. This
new information does not raise any concern for human and animal health and the environment
regarding the four-event stack maize and its subcombinations.
Given the absence of safety concerns for foods and feeds from the four-event stack maize and all
its subcombinations, the GMO Panel considers that post-market monitoring of these products is not
necessary. The post-market environmental monitoring plan and reporting intervals are in line with the
intended uses of the four-event stack maize and its subcombinations.
In conclusion, the GMO Panel considers that maize MON 87427 9 MON 89034 9 MIR162 9 NK603
and its subcombinations, as described in this application, are as safe as the non-GM comparator and
the tested non-GM reference varieties with respect to potential effects on human and animal health
and the environment.
Documentation as provided to EFSA
• Letter from the Competent Authority of Netherlands received on 18 February 2016 concerning
a request for authorisation of the placing on the market of maize MON 87427 9 MON 89034 9
MIR162 9 NK603 (EFSA-GMO-NL-2016-131) submitted in accordance with Regulation (EC)
No 1829/2003 by Monsanto Europe S.A./N.V.
• Application EFSA-GMO-NL-2016-131 validated by EFSA, 31 May 2016
• Request for supplementary information to the applicant (on behalf of EURL-GMFF),
7 June 2016
• Request for supplementary information to the applicant, 9 June 2016
• Receipt of supplementary information from the applicant, 6 July 2016
• Request for supplementary information to the applicant, 3 August 2016
• Receipt of supplementary information from the applicant, 29 September 2016
• Request for supplementary information to the applicant, 8 November 2016
• Receipt of supplementary information from the applicant, 9 January 2017
• Receipt of supplementary information from the applicant, 10 January 2017
• Request for supplementary information to the applicant, 24 February 2017
• Request for supplementary information to the applicant, 11 April 2017
• Receipt of supplementary information from the applicant, 21 April 2017
• Request for supplementary information to the applicant, 18 May 2017
• Receipt of supplementary information from the applicant, 11 July 2017
• Receipt of supplementary information from the applicant, 18 July 2017
• Request for supplementary information to the applicant, 1 August 2017
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• Request for supplementary information to the applicant, 1 September 2017
• Receipt of supplementary information from the applicant, 14 September 2017
• Receipt of supplementary information from the applicant, 25 September 2017
• Receipt of spontaneous information from the applicant, 20 December 2017
• Request for supplementary information to the applicant, 15 February 2018
• Request for supplementary information to the applicant, 23 March 2018
• Receipt of supplementary information from the applicant, 24 May 2018
• Receipt of spontaneous information from the applicant, 24 September 2018
• Receipt of supplementary information from the applicant, 16 October 2018
• Request for supplementary information to the applicant, 6 November 2018
• Request for supplementary information to the applicant, 8 November 2018
• Receipt of supplementary information from the applicant, 8 November 2018
• Receipt of supplementary information from the applicant, 23 November 2018
• Receipt of supplementary information from the applicant, 30 November 2018
• Request for supplementary information to the applicant, 21 December 2018
• Request for supplementary information to the applicant, 18 January 2019
• Request for supplementary information to the applicant, 24 January 2019
• Receipt of supplementary information from the applicant, 22 March 2019
• Receipt of supplementary information from the applicant, 25 March 2019
• Receipt of supplementary information from the applicant, 26 March 2019
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Abbreviations
ADF acid detergent fibre
bw body weight
CaMV cauliflower mosaic virus
CRM comparative relative maturity
CTP Chloroplast transit peptide
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
FMV Figwort Mosaic Virus
GM genetically modified
GMO genetically modified organism
GMO Panel EFSA Panel on Genetically Modified Organisms
HGT horizontal gene transfer
HR homologous recombination
IgE immunoglobulin E
LOD limit of detection
NDF neutral detergent fibre
NEP newly expressed protein
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PCR polymerase chain reaction
PMEM post-market environmental monitoring
PMI phosphomannose isomerase
T-DNA transfer-deoxyribonucleic acid
TDF total dietary fibre
UTR untranslated region
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Appendix A – Protein expression data
Means, standard deviation and ranges of protein levels (lg/g dry weight) from maize MON 87427 9 MON 89034 9 MIR162 9 NK603 (treated with
glyphosate), MON 87427 (treated with glyphosate), MON 89034 (not treated), MIR162 (not treated) and NK603 (treated with glyphosate) from field trials
performed in the US in 2013(a)
Protein Event(s) Leaf (V2–V4)
Whole Plant
(V10–V11)
Forage(R5) Root(V2–V4) Root(R5) Grain(R6) Pollen(R1)
CP4
EPSPS(b)
MON 87427 3 MON 89034 3
MIR162 3 NK603
1100(c)  400(d)
(260–1700)(e)
430  140
(280–790)
300  41
(240–390)
390  99
(240–610)
160  18
(120–200)
13  2.8
(9.4–18)
290  51
(180–350)
MON 87427 950  150
(620–1300)
380  110
(240–630)
160  31
(98–220)
260  44
(190–330)
120  34
(71–180)
5.4  1.7
(2.0 – 8.9)
< LOD(f),(g)
NK603 170  120
(79–480)
110  19
(71–140)
81  17
(49–100)
130  43
(70–220)
72  21
(48–130)
6.9  1.1
(4.5–8.5)
290  56
(190–380)
Cry1A.105 MON 87427 3 MON 89034 3
MIR162 3 NK603
450  91
(320–630)
94  42
(49–180)
32  13
(17–59)
64  12
(48–96)
15  3.5
(8.4–21)
2.4  0.86
(1.4–3.9
11  3.0
(5.9–18)
MON 89034 520  100
(380–690)
91  31
(50–170)
39  15
(13–68)
59  12
(37–78)
14  3.9
(4.0–20)
2.2  0.65
(1.3–3.2)
11  3.4
(5.9–16)
Cry2Ab2 MON 87427 3 MON 89034 3
MIR162 3 NK603
130  39
(49–210)
31  13
(16–58)
29  5.0
(21–43)
42  13
(18–70)
11  3.0
(2.9–16)
0.69  0.17
(0.50–1.0)
0.57  0.13
(0.35–0.81)
MON 89034 110  36
(62–190)
28  8.7
(15–53)
31  6.1
(20–42)
36  19
(15–77)
13  2.7
(10–20)
0.81  0.25
(0.43–1.7)
0.60  0.11
(0.40–0.77)
Vip3Aa20 MON 87427 3 MON 89034 3
MIR162 3 NK603
220  62
(150–360)
95  30
(73–170)
100  22
(68–150)
100  27
(60–140)
56  23
(30–110)
59  14
(41–95)
91  7.8
(82–110)
MIR162 270  53
(190–350)
94  22
(70–150)
110  14
(83–130)
110  25
(65–150)
54  25
(17–110)
50  16
(18–76)
87  11
(68–110)
PMI MON 87427 3 MON 89034 3
MIR162 3 NK603
11  2.3
(7.8–15)
5.6  1.5
(0.40–9.3)
4.4  0.90
(3.2–6.8)
6.3  1.4
(3.6–7.7)
2.5  0.68
(1.5–4.0)
1.4  0.24
(0.87–1.9)
3.0  0.54
(2.1–4.2)
MIR162 11  1.8
(8.7–15)
6.1  1.1
(3.8–8.1)
4.3  0.80
(3.2–5.9)
7.1  1.5
(4.7–9.3)
2.2  0.79
(1.0–3.6)
1.2  0.36
(0.21–1.8)
2.2  0.34
(1.7–2.6)
EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase; PMI: phosphomannose isomerase.
(a): Number of sample is n = 20 except for: n = 19 for whole plant (for all newly expressed proteins), forage and root/R5 (for CP4 EPSPS); n = 16 for root/V2-V4 (for Cry1A.105, Cry2Ab2,
Vip3Aa20 and PMI).
(b): EPSPS levels in the maize MON 87427 9 MON 89034 9 MIR162 9 NK603 are a sum of two protein variants, CP4 EPSPS (expressed in MON 87427 and NK603) and CP4 EPSPS L214P
(expressed in NK603)
(c): Mean.
(d): Standard deviation.
(e): Range.
(f): LOD: limit of detection.
(g): Due to specific insert design, little to no CP4 EPSPS protein is expected to be produced in pollen.
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Appendix B – List of additional unpublished studies performed by or on
behalf of the applicant with regard to the evaluation of the safety of maize
MON 87427 3 MON 89034 3 MIR162 3 NK603 for humans, animals and
the environment
Study
identification
Title
MSL0022349 Immunodetection of CP4 EPSPS in Corn Grain of MON 87427 Following Heat Treatment
MSL0024759 Immunodetection of CP4 EPSPS following heat treatment
MSL0025578 Compositional Analyses of Maize Forage and Grain from MON 87427 9 MON
89034 9 MIR162 9 NK603 Grown in the United States in 2013
MSL0026080 Phenotypic Evaluation and Environmental Interactions of Maize MON 87427 9 MON
89034 9 MIR162 9 NK603 in 2013 U.S. Field Trials
MSL0026199 Phenotypic Evaluation of Maize MON 87427 9 MON 89034 9 MIR162 9 NK603 with
Herbicide Treatment in 2013 U.S. Field Trials
MSL0026201 Southern Blot Analyses to Confirm the Presence of MIR162 in the Combined Trait Maize
Product MON 87427 9 MON 89034 9 MIR162 9 NK603
MSL0026228 Comparison of Lipid Transfer Protein (LTP) Expression Levels from MON 87427 9 MON
89034 9 MIR162 9 NK603 with Conventional Control Maize
MSL0026686 Amended Report for MSL0025842: Southern Blot Analyses to Confirm the Presence of MON
87427, MON89034 and NK603 in the Combined Trait Maize Product MON 87427 9 MON
89034 9 MIR162 9 NK603
SCR-2014-0178 Compositional Analyses of Maize Forage and Grain from MON 87427 9 MON
89034 9 MIR162 9 NK603 Grown in the United States in 2013: Individual Site Analysis
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